In short
Clinical trials are studying Inclisiran Sodium in people with atherosclerotic cardiovascular disease and hypercholesterolemia. These studies look at how well it lowers LDL cholesterol compared with other treatments, and they also measure safety and overall effectiveness.
Key points
- Clinical trials of Inclisiran Sodium are studying people with atherosclerotic cardiovascular disease and hypercholesterolemia. The main trial is a Phase 3, randomized, multicenter, open-label study with 400 participants. It compares Inclisiran Sodium with bempedoic acid, together with standard cholesterol-lowering treatment. The key outcome is the percent change in LDL-C, or bad cholesterol, from baseline to day 150. The trial is completed and focused on how well the treatment lowers LDL cholesterol.
Trial overview
This trial, called VICTORION-CHALLENGE, was a randomized, multicenter, open-label study of Inclisiran Sodium in people with hypercholesterolemia and atherosclerotic cardiovascular disease. It was completed and included 400 participants.
Who was studied
The target population was people with atherosclerotic cardiovascular disease, which means heart or blood vessel disease linked to plaque buildup, and hypercholesterolemia, which means high cholesterol. The trial also used background cholesterol treatment with the best tolerated statin dose, with or without ezetimibe.
Statins named in the trial data were atorvastatin and rosuvastatin, and ezetimibe was also listed as part of standard treatment. This means the study was focused on people already receiving usual cholesterol care, not on untreated participants.
Treatments compared in the study
The study compared Inclisiran Sodium with bempedoic acid for lowering LDL cholesterol. LDL cholesterol is often called "bad" cholesterol because high levels can raise heart risk.
Inclisiran Sodium was studied as part of a combination approach with standard care, and the trial aimed to show better LDL-C lowering than bempedoic acid. The study title also describes it as a superiority trial, which means it was designed to see whether one treatment works better than the other.
Study design and phase
This was a Phase 3 trial, which usually means the treatment is being tested in a larger group to compare how well it works in real patients. It was also randomized, so participants were assigned by chance to the study treatment groups.
The study was multicenter, meaning it took place at more than one site. It was open-label, so the people in the study and the research team knew which treatment was being given.
What the trial measured
The main endpoint was the percent change from baseline in LDL-C levels at day 150. Baseline means the starting measurement before treatment begins, and day 150 means the result was checked about five months later.
This endpoint shows how much the treatment lowered LDL cholesterol over time. In simple terms, the study asked whether Inclisiran Sodium could reduce bad cholesterol more than bempedoic acid when both were used with standard care.
Why this trial matters
People with atherosclerotic cardiovascular disease often need strong cholesterol control because high LDL-C can increase the risk of future heart and blood vessel problems. This trial adds information about how Inclisiran Sodium performs in that setting when compared with another cholesterol-lowering drug.
The trial data focus on one main study, so the most important message is that Inclisiran Sodium is being evaluated as part of a strategy to improve LDL-C lowering in patients who already have cardiovascular disease and high cholesterol.